⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 2, 2024

Figure S1 from The CDK4/6 Inhibitor Palbociclib Synergizes with ATRA to Induce Differentiation in AML

Linhui Hu Qian Li Jiyu Wang Huiping Wang Xiyang Ren Keke Huang Yangyang Wang Xue Liang Lianfang Pu Shudao Xiong Zhimin Zhai

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure S1. The mutation frequency of CDK4/6-cyclin D pathway genes, CDKN1A and CDKN2A in 531 AML patients (A). The expression of CDKN1A and CDKN2A was compared between AML and healthy donors in the BeatAML database. * Represent P<0.05.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hu et al. (2024) studied this question.

synapsesocial.com/papers/68e61b6eb6db6435875adb5d https://doi.org/10.1158/1535-7163.26145182

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S2 from The CDK4/6 Inhibitor Palbociclib Synergizes with ATRA to Induce Differentiation in AML2024
2Figure S3 from The CDK4/6 Inhibitor Palbociclib Synergizes with ATRA to Induce Differentiation in AML2024
3Data from The CDK4/6 Inhibitor Palbociclib Synergizes with ATRA to Induce Differentiation in AML2024
4Figure S4 from The CDK4/6 Inhibitor Palbociclib Synergizes with ATRA to Induce Differentiation in AML2024
5The CDK4/6 inhibitor Palbociclib synergizes with ATRA to induce differentiation in AML2024 · 10 citations